글로벌 iPS 세포 (유도 만능 줄기 세포) 시장 (2023-2030) : 간세포, 섬유 아세포

■ 영문 제목 : Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development, Toxicology Research), End-user, By Region, And Segment Forecasts, 2023 - 2030

Grand View Research가 발행한 조사보고서이며, 코드는 GRV23NOV022 입니다.■ 상품코드 : GRV23NOV022
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 9월
■ 페이지수 : 180
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 바이오
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산₩8,032,500견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산₩9,382,500견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산₩12,082,500견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 iPS 세포 (유도 만능 줄기 세포) 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 iPS 세포 (유도 만능 줄기 세포) 시장 규모는 2030년까지 30. 9억 달러에 달할 것으로 예상되며, 2023년부터 2030년까지 연평균 10. 61%의 성장률을 기록할 것으로 전망됩니다. iPS 세포 (유도 만능 줄기 세포) 시장은 빠르게 성장하고 있습니다. iPS 세포 (유도 만능 줄기 세포)는 백혈병, 척수손상, 심혈관질환, 당뇨병과 같은 질병을 치료하거나 퇴치하기 위해 신체에 필수적인 모든 세포와 조직을 생성할 수 있다는 점이 주요 활용 이유입니다.

시장 확대를 촉진하는 다른 요인으로는 연구비 증가, 유전체학 이니셔티브의 증가, 개인 맞춤형 치료에서 유전체 공학의 적용이 급증하고 있다는 점 등이 있습니다. 그 결과, iPSC의 도입이 가속화되어 시장 수익 성장으로 이어졌습니다. 예를 들어, 2020년 10월 Axxam S. p. A. 와 후지필름 셀룰러 다이내믹스(FUJIFILM Cellular Dynamics, Inc.)는 신약 개발 과정을 촉진하기 위한 전략적 파트너십을 발표했습니다. 이번 파트너십을 통해 신약개발 연구자들은 과학자들과 함께 hiPSC 기반 분석의 통합 플랫폼에 접근할 수 있으며, 표적 평가, 하이스루풋 스크리닝(HTS) 및 고함량 스크리닝을 가능하게 하는 최첨단 신약개발 기술을 이용할 수 있게 됩니다.

최근 몇 년 동안 의료 개발 및 연구에 대한 투자가 크게 확대되고 있으며, 이러한 추세는 예측 기간 동안 iPS 세포 (유도 만능 줄기 세포) 수요에 큰 영향을 미칠 것으로 예상됩니다. 정밀의료에서 인간 iPSC 세포주의 적용 범위가 확대되고 줄기세포 치료 응용에 대한 관심이 높아지면서 iPS 세포 (유도 만능 줄기 세포) 시장 확대를 촉진하는 중요한 요인이 될 것으로 예상됩니다. 예를 들어, 양사의 공동 성명에 따르면 2021년 3월 사나 바이오테크놀로지(Sana Biotechnology, Inc.)는 후지필름 셀룰러 다이내믹스의 iPSC 플랫폼을 상업적으로 이용 가능한 세포치료제 제조에 사용할 수 있는 허가를 취득했습니다. 세포 치료는 세포, 조직, 장기 등 인간의 생물학을 개선, 복구, 대체할 수 있습니다.

코로나19 팬데믹 기간 동안 연구 활동이 활발해진 것도 iPS 세포를 이용한 연구에 힘을 실어주었습니다. 또한, SARS CoV-2 감염을 관리하기 위한 새로운 치료법과 치료법을 발견하기 위한 과학자들의 지속적인 노력으로 연구 도구로서 iPSC의 필요성이 증가하고 있습니다. 또한, iPSC는 생리학적으로 동등한 기관 및 장기 모델을 생성할 수 있기 때문에 인간의 바이러스 감염 병태생리학 연구에 활용되며 이는 산업 성장을 촉진하고 있습니다.

또한, iPS 세포와 관련된 다양한 과학적 활동에 초점을 맞춘 산업의 성장과 함께 정부 및 상업 부문의 자금 지원이 확대되고 있으며, 다양한 기관을 통해 사람들의 줄기세포에 대한 인식이 높아지고 있습니다. 그러나 세포 초기화에 드는 높은 비용, 윤리적 문제, 긴 과정 등의 문제는 iPS 세포 (유도 만능 줄기 세포) 산업의 성장을 어느 정도 저해하고 있습니다. 또한 낮은 효율성, 잠재적 종양 위험, 불충분한 프로그래밍도 iPSC 시장 확대를 제한하는 요인으로 꼽히고 있습니다.

iPS 세포 (유도 만능 줄기 세포) 시장 보고서 주요 내용

- 유래 세포 유형별로는 섬유아세포 부문이 2022년 30. 48%로 가장 큰 점유율을 차지했습니다. 피부 질환에 대한 잠재적 치료법으로 섬유아세포에 대한 의료 종사자들의 선호도가 높아지면서 이 부문의 성장을 견인하고 있습니다.

- 용도별로는 의약품 개발 부문이 2022년 49. 09%로 가장 큰 점유율을 차지할 것으로 예상됩니다. 만성 질환의 확산, 좌식 생활 습관 등으로 인해 개인 맞춤형 치료에 대한 수요가 증가하고 있으며, iPS 세포를 이용한 의약품 개발에 대한 제약 및 생명 공학 기업의 관심이 높아지면서 산업 성장을 촉진하고 있습니다.

- 최종 사용자별로는 제약 및 생명 공학 기업이 2022년 59. 77%로 가장 큰 점유율을 차지할 것으로 예상됩니다. 이 부문은 iPS 세포 (유도 만능 줄기 세포)를 이용한 다양한 질병에 대한 다양한 줄기세포 제품 및 기술을 제조 및 개발하기 때문에 시장을 지배할 것으로 예상됩니다.

- 2022년에는 북미가 42. 36%로 가장 큰 점유율을 차지할 것으로 예상됩니다. 이는 의약품 연구, 독성 테스트, 질병 모델링에서 혁신적인 시스템 및 기술의 사용이 증가하고 있으며, 이 지역에서 줄기세포 치료의 수용이 증가하고 있는 것이 시장을 이끄는 주요 요인으로 작용하고 있다고 전했습니다.
■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변수/동향/범위
Chapter 4. 세계의 iPS 세포 (유도 만능 줄기 세포) 시장 : 유래세포 종류별 분석
Chapter 5. 세계의 iPS 세포 (유도 만능 줄기 세포) 시장 : 용도별 분석
Chapter 6. 세계의 iPS 세포 (유도 만능 줄기 세포) 시장 : 최종 용도별 분석
Chapter 7. 세계의 iPS 세포 (유도 만능 줄기 세포) 시장 : 지역별 분석
Chapter 8. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Information analysis
1.2.2. Market formulation & data visualization
1.2.3. Data validation & publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Europe Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Increase in research and development activities in stem cells therapies
3.3.2. Surge in adoption of personalized medicine
3.4. Market Restraint Analysis
3.4.1. Lack of awareness regarding stem cell therapies
3.4.2. High cost of treatment
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Derived Cell Type Business Analysis
4.1. Global induced pluripotent stem cells market: Derived Cell Type Movement Analysis
4.2. Hepatocytes
4.2.1. Hepatocytes Market, 2018 – 2030 (USD Million)
4.3. Fibroblasts
4.3.1. Fibroblasts Market, 2018 – 2030 (USD Million)
4.4. Keratinocytes
4.4.1. Keratinocytes Market, 2018 – 2030 (USD Million)
4.5. Amniotic Cells
4.5.1. Amniotic Cells Market, 2018 – 2030 (USD Million)
4.6. Others
4.6.1. Others Market, 2018 – 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Global induced pluripotent stem cells market: Application Movement Analysis
5.2. Drug Development
5.2.1. Drug Development Market, 2018 – 2030 (USD Million)
5.3. Tissue Engineering & Regenerative Medicine
5.3.1. Tissue Engineering & Regenerative Medicine Market, 2018 – 2030 (USD Million)
5.3.2. Neurology
5.3.2.1. Neurology Market, 2018 – 2030 (USD Million)
5.3.3. Orthopedics
5.3.3.1. Orthopedics Market, 2018 – 2030 (USD Million)
5.3.4. Oncology
5.3.4.1. Oncology Market, 2018 – 2030 (USD Million)
5.3.5. Cardiovascular and Myocardial Infraction
5.3.5.1. Cardiovascular and Myocardial Infraction Market, 2018 – 2030 (USD Million)
5.3.6. Diabetes
5.3.6.1. Diabetes Market, 2018 – 2030 (USD Million)
5.3.7. Others
5.3.7.1. Others Market, 2018 – 2030 (USD Million)
5.4. Toxicology Research
5.4.1. Toxicology Research Market, 2018 – 2030 (USD Million)
5.5. Disease Modeling
5.5.1. Disease Modeling Market, 2018 – 2030 (USD Million)
Chapter 6. End-User Business Analysis
6.1. Global induced pluripotent stem cells market: End-User Movement Analysis
6.2. Academic & Research Institutes
6.2.1. Academic & Research Institutes Market, 2018 – 2030 (USD Million)
6.3. Pharmaceutical & Biotechnology Companies
6.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Million)
6.4. Others
6.4.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Global Induced Pluripotent Stem Cells Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. Target Disease Prevalence
7.2.2.5. U.S. induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Target Disease Prevalence
7.2.3.5. Canada induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe Induced Pluripotent Stem Cells Market, 2018 – 2030 (USD Million)
7.3.2. Germany
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. Target Disease Prevalence
7.3.2.5. Germany induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Target Disease Prevalence
7.3.3.5. UK induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. Target Disease Prevalence
7.3.4.5. France induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Target Disease Prevalence
7.3.5.5. Italy induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Target Disease Prevalence
7.3.6.5. Spain induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Target Disease Prevalence
7.3.7.5. Denmark induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Target Disease Prevalence
7.3.8.5. Sweden induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Target Disease Prevalence
7.3.9.5. Norway induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Target Disease Prevalence
7.4.2.5. Japan induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Target Disease Prevalence
7.4.3.5. China induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Target Disease Prevalence
7.4.4.5. India induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Target Disease Prevalence
7.4.5.5. South Korea induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Target Disease Prevalence
7.4.6.5. Australia induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. Target Disease Prevalence
7.4.7.5. Thailand induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Target Disease Prevalence
7.5.2.5. Brazil induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Target Disease Prevalence
7.5.3.5. Mexico induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Target Disease Prevalence
7.5.4.5. Argentina induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. MEA induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Target Disease Prevalence
7.6.2.5. South Africa induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Target Disease Prevalence
7.6.3.5. Saudi Arabia induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. Target Disease Prevalence
7.6.4.5. UAE induced pluripotent stem cells market, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Target Disease Prevalence
7.6.5.5. Kuwait induced pluripotent stem cells market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. STEMCELL Technologies Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Cellular Engineering Technologies Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. REPROCELL Inc.
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Takara Bio, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Axol Bioscience Ltd.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Fate Therapeutics, Inc.
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. FUJIFILM Corporation (FUJIFILM Cellular Dynamics, Inc.)
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Cynata Therapeutics Limited
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Evotec SE
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Astellas Pharma Inc.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables

Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 Global Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 4 Global Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 5 Global Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 6 North America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 7 North America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 8 North America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 9 North America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 10 U.S. Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 11 U.S. Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 12 U.S. Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 13 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 14 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 15 Canada Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 16 Europe Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 17 Europe Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 18 Europe Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 19 Europe Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 20 UK Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 21 UK Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 22 UK Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 23 Germany Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 24 Germany Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 25 Germany Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 26 France Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 27 France Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 28 France Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 29 Italy Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 30 Italy Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 31 Italy Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 32 Spain Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 33 Spain Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 34 Spain Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 35 Denmark Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 36 Denmark Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 37 Denmark Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 38 Sweden Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 39 Sweden Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 40 Sweden Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 41 Norway Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 42 Norway Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 43 Norway Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 48 China Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 49 China Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 50 China Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 51 Japan Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 52 Japan Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 53 Japan Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 54 India Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 55 India Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 56 India Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 57 South Korea Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 58 South Korea Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 59 South Korea Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 60 Australia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 61 Australia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 62 Australia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 63 Thailand Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 64 Thailand Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 65 Thailand Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 66 Latin America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 67 Latin America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 68 Latin America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 69 Latin America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 70 Brazil Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 71 Brazil Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 72 Brazil Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 73 Mexico Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 74 Mexico Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 75 Mexico Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 76 Argentina Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 77 Argentina Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 78 Argentina Induced Pluripotent Stem Cells Market by End-User, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 83 South Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 84 South Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 85 South Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 89 UAE Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 90 UAE Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 91 UAE Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 92 Kuwait Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 94 Kuwait Induced Pluripotent Stem Cells Market By End-Use, 2018 - 2030 (USD Million)
Table 95 Participant’s Overview
Table 96 Financial Performance
Table 97 Key Companies Undergoing Expansions
Table 98 Key Companies Undergoing Acquisitions
Table 99 Key Companies Undergoing Collaborations
Table 100 Key Companies Launching New Products/Services
Table 101 Key Companies Undergoing Partnerships
Table 102 Key Companies Undertaking Other Strategies
※본 조사보고서 [글로벌 iPS 세포 (유도 만능 줄기 세포) 시장 (2023-2030) : 간세포, 섬유 아세포] (코드 : GRV23NOV022) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 iPS 세포 (유도 만능 줄기 세포) 시장 (2023-2030) : 간세포, 섬유 아세포] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!